Researcher
Sabine Tejpar
- Disciplines:Oncology
Affiliations
- Digestive Oncology (Division)
Responsible
From1 Aug 2022 → Today - Digestive Oncology (Division)
Member
From1 Aug 2022 → Today - Molecular Digestive Oncology (Division)
Member
From1 Jan 2012 → 31 Jul 2022 - Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 2003 → 31 Dec 2011
Projects
41 - 50 of 56
- Targeting ZEB pathways to tackle aggressive (colorectal) cancer (ZENTACC).From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- Characterization of the transcriptome interactions between host and gut microbiota in health and diseaseFrom1 Oct 2017 → 30 Sep 2020Funding: FWO fellowships
- ZIC2 acts as a chromatin modifier to determine cell fate specification in stem cells and cancer.From1 Jan 2017 → 31 Dec 2020Funding: Foundations, funds and other with scientific goal
- When is a polyp born to be bad?From1 Jan 2017 → 31 Dec 2020Funding: Foundations, funds and other with scientific goal
- In vivo and in vitro study on the development of resistance clones to targeted therapies in colorectal cancer in molecular subgroups.From1 Apr 2016 → 31 Jul 2021Funding: FWO research project
- Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancerFrom1 Oct 2015 → 30 Nov 2020Funding: H2020 - Health, demographic change and wellbeing
- The role of the proprotein convertase furin in cancerFrom22 Sep 2014 → 3 Aug 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
- Linking miRNA-based colorectal cancer subtypes to sensitivity to targeted therapies.From1 Jan 2014 → 31 May 2017Funding: FWO research project
- Validation of Aprataxin as a biomarker of response to Topoisomerase I inhibitors in cancer patients.From1 Jan 2013 → 30 Jun 2017Funding: FWO research project
- Identification of candidate biomarkers of intrinsic and acquired resistance to anti-angiogenic agents in metastatic colorectal cancer.From1 Jan 2013 → 31 Dec 2014Funding: Private funding of national origin - undefined
Publications
1 - 10 of 247
- Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology.(2024)
Authors: Stefania Tuveri, Lore Lannoo, Liesbeth Lenaerts, Sabine Tejpar, Bernard Thienpont, Joris Vermeesch
Pages: 2220 - Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer(2024)
Authors: Sabine Tejpar
- Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer(2024)
Authors: Sara Verbandt, An Coosemans, Sabine Tejpar
- Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells.(2024)
Authors: Jenny Sprooten, Isaure Vanmeerbeek, Sabine Tejpar, Steven De Vleeschouwer, Abhishek Garg
Pages: 101377 - Trial watch: chemotherapy-induced immunogenic cell death in oncology(2023)
Authors: Jenny Sprooten, Isaure Vanmeerbeek, Stefan Naulaerts, Lisa Kinget, An Coosemans, Steven De Vleeschouwer, Els Wauters, Sabine Tejpar, Benoit Beuselinck, Sigrid Hatse, et al.
- Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study(2023)
Authors: Sabine Tejpar
- Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer(2023)
Authors: Sara Verbandt, Isaure Vanmeerbeek, Jenny Sprooten, Gert De Hertogh, Xavier Sagaert, Albert Wolthuis, Stefan Naulaerts, Sabine Tejpar, Abhishek Garg
- Molecular portraits of colorectal cancer morphological regions(2023)
Authors: Sabine Tejpar
- Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)(2023)
Authors: Lisa Kinget, Isaure Vanmeerbeek, Diether Lambrechts, Bram Boeckx, Maarten Albersen, Sabine Tejpar, Benoit Beuselinck, Abhishek Garg
Pages: S1026 - S1027 - Efficacy of olaparib in advanced cancers with germline or somatic tumor mutations in BRCA1, BRCA2, CHEK2 and ATM: A Belgian precision tumor-agnostic phase II study(2023)
Authors: Sabine Tejpar
Pages: S242 - S242
Patents
1 - 1 of 1
- Colon cancer (Inventor)